clinical trial failures

The biotech sector could see a period of relative stability, according to a time-series analysis of the NASDAQ Biotech Index. In recent years, however, performance of the NBI has had little bearing on the rate of layoffs in the pharma and biotech sectors. A statistical analysis of the relationship between the NBI performance and the…

Companies across the industry have contributed to biotech layoffs in early 2024, driven by factors ranging from operational restructuring to strategic pivots and clinical trial failures, with major hubs like California and Massachusetts bearing the brunt of the impact. A recent analysis assembled with the help a machine learning technique known as clustering reveals a pattern of job…

Biotech layoffs continue to pummel the industry in early 2024 — albeit at a slightly lower clip than in 2023. Smaller firms continue to bear the brunt of funding woes and disappointing clinical data. From January to February, operational reorganizations fueled 45 layoff announcements, followed closely by strategic pivots in 37 events. Other common drivers…